Q1 Earnings Estimate for DNLI Issued By HC Wainwright

Key Points

• HC Wainwright forecasts a Q1 2027 loss of $0.60 per share for Denali Therapeutics, with quarterly losses projected to narrow to $0.53 per share by Q4 2027.
• Denali’s latest quarter beat expectations, with revenue of $17.78 million versus $12.67 million expected. Its $70.1 million net income included a one-time $194 million gain from selling a Priority Review Voucher, while the company forecast Q4 product revenue of $30 million to $32 million.
• Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $36.15. Morgan Stanley raised its target to $42 and maintained an Overweight rating.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued on Wednesday, November 4th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.60) per share for the quarter. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Denali Therapeutics' Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.53) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same quarter last year, the business posted ($0.74) earnings per share.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley upped their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. B. Riley Financial boosted their target price on Denali Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Wall Street Zen upgraded Denali Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, October 24th. Finally, UBS Group raised their price target on Denali Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a report on Friday, August 7th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $36.15.

Denali Therapeutics Stock Up 7.8%

Shares of NASDAQ:DNLI opened at $20.96 on Thursday. The firm has a fifty day moving average price of $20.35 and a two-hundred day moving average price of $21.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30. The company has a market cap of $3.35 billion, a price-to-earnings ratio of -12.12 and a beta of 1.08.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. BlackRock Inc. purchased a new position in Denali Therapeutics during the second quarter valued at $360,759,000. Dimensional Fund Advisors LP grew its stake in shares of Denali Therapeutics by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock worth $51,687,000 after acquiring an additional 317,872 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock worth $35,932,000 after acquiring an additional 1,819,339 shares during the last quarter. Defilade Capital Management L.P. increased its holdings in shares of Denali Therapeutics by 107.1% during the first quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company's stock valued at $26,111,000 after acquiring an additional 703,256 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Denali Therapeutics during the second quarter valued at $31,660,000. Institutional investors own 92.92% of the company's stock.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. This represents a 1.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 9.70% of the company's stock.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH sales and Q4 outlook: Net product revenue reached $17.8 million in the second full commercial quarter. Denali expects Q4 2026 product revenue of $30 million to $32 million, signaling substantial near-term growth. Denali Q3 2026 financial results and business highlights
• Positive Sentiment: Revenue beat estimates: Q3 revenue of $17.78 million topped analyst expectations of $12.67 million. The company also reported a $70.1 million net income for the quarter. Denali Therapeutics soars on earnings beat
• Positive Sentiment: Analyst targets raised: Morgan Stanley lifted its target to $42 and maintained Overweight; Wedbush raised its target to $24 and maintained Outperform. BTIG reaffirmed Buy with a $39 target. The higher targets reflect analyst optimism, though they are not guarantees of future performance. Read More., Read More., Read More.
• Positive Sentiment: Pipeline and balance sheet: Denali said a 2027 BLA filing for zafinofusp is on track and expects data from five TransportVehicle programs in 2027. Cash, equivalents and marketable securities totaled $1.0 billion. Denali Q3 2026 financial results and business highlights
• Neutral Sentiment: Earnings quality context: Q3 net income included a one-time $194 million gain from selling a Priority Review Voucher, so the reported profit is not solely reflective of recurring operations. Denali Q3 2026 financial results and business highlights

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.